Search PubMed⌕ Search

PubMed · 6439639

[Peripheral venous tolerance of a hyperosmolar basic solution].

Abstract

A controlled open clinical trial was carried out to compare the peripheral venous tolerance of patients receiving a hyperosmolar basic nutrition solution (3% amino acids, carbohydrates and electrolytes, 806 mosm/l) with that of patients receiving an isoosmolar electrolyte solution (299 mosm/l). 13 patients received the basic solution, 11 the electrolyte solution. The study was terminated after 4 days. For comparison the infusion time and local venous irritation of each patient were recorded. In both the infusion time and local irritation a slight trend in favour of the electrolyte solution was found, which, however, did not reach statistical significance. We conclude, that under normal clinical circumstances a hyperosmolar basic nutrition solution does not cause a higher rate of peripheral venous irritations compared with an isoosmolar electrolyte solution and should be administered to patients with an expected infusion time of not longer than 4 days.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H U Comberg, N Senninger, M Wagner. 1984. [Peripheral venous tolerance of a hyperosmolar basic solution].. https://pubmed.ncbi.nlm.nih.gov/6439639/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Chimeric structural isomer fragments as cost-efficient internal standards for amino acid quantification by mass spectrometry.

Amino acid (AA) profiles from body fluids such as blood and urine are clinical indicators for diagnosing metabolic and hepatic diseases. Current quantitative methods, such as liquid chromatography-mass spectrometry (LC-MS) with isotopically labelled internal standards (ISs), are costly and technically demanding. This study proposes a cost-efficient alternative using structural isomers as ISs in a direct liquid infusion (DLI) tandem mass spectrometry (MS/MS) approach. The method leverages chimeric spectra and fragment intensity ratios to quantify AAs, demonstrating high linearity and precision even with a 3D ion trap mass analyser. This approach offers a viable strategy for AA quantification in preventive medicine, particularly for screening metabolic diseases such as phenylketonuria, diabetes, and liver dysfunction.

Amino Acids↗

Surface engineering of poly(D,L-lactic acid) by entrapment of chitosan-based derivatives for the promotion of chondrogenesis.

Chitosan and chitosan-amino acid derivatives were explored to engineer poly(D,L-lactic acid) (PDL-LA) as an extracellular matrix-like surface to promote cell adhesion and growth. Four kinds of chitosan-amino acid derivatives were prepared to mimic the carbohydrate moieties of cell matrix glycoprotein. The chitosan-amino acid derivatives were characterized by using Fourier transform infrared and ultraviolet spectra. The amino acid content on chitosan-amino acid derivatives was determined by using a ninhydrin-ultraviolet method. A new strategy, entrapment, was therefore used to modify the PDL-LA membrane with chitosan and chitosan-amino acid derivatives. The results of X-ray photoelectron spectroscopy, attenuated total reflectance-Fourier transform infrared, and contact angle confirmed that a stable thin film of chitosan and its derivatives can be entrapped on the surface of the PDL-LA membrane. From the results of chondrocyte cytocompatibility, MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] assays, and cell morphology, the chitosan-amino acid derivative modified PDL-LA membranes were shown to promote chondrogenesis. The novel surface treatment method combines the good mechanical property of PDL-LA with the good cytocompatibility of chitosan derivatives, which may have potential for tissue engineering.

Amino Acids↗

A new vascular prosthesis coated with polyamino-acid urethane copolymer (PAU) to enhance endothelialization.

Clinically available synthetic ePTFE vascular grafts frequently fail when used for small-diameter arterial substitution. The lower long-term patency of ePTFE grafts is due mainly to thrombogenicity and poor healing. We developed a new small-diameter (1.5-mm) ePTFE vascular prosthesis coated with polyamino-acid urethane copolymer (PAU) to enhance endothelialization. Coating with PAU made the hydrophobic ePTFE vascular graft hydrophilic. Scanning electron microscopy (SEM) observation showed that PAU was homogeneously coated on the ePTFE graft while maintaining the graft's porous structure. Fourier transform infrared attenuated total reflectance (FTIR-ATR) spectra showed PAU was present on graft inner surfaces. Noncoated and PAU-coated ePTFE vascular grafts were implanted into the rat abdominal aorta and evaluated within 1 week and at 8 weeks after implantation. We evaluated the extent of neoendothelialization by SEM, light microscopy, and immunohistochemical staining. Noncoated grafts showed partial endothelialization at proximal and distal areas of grafts but none at midsection. One-percent PAU-coated grafts showed incomplete neoendothelialization, but endothelial cells were observed in the midsection of grafts. Three-percent PAU-coated ePTFE grafts showed complete endothelialization with typical endothelial cell layers under SEM and histologic observation. Immunohistochemical staining also showed that an endothelial cell lining positively reacted with anti-von Willebrand factor (endothelial cell marker) antibody. We conclude that PAU-coated ePTFE vascular grafts enhance endothelialization.

Amino Acids↗